Perspectives on farnesyl transferase inhibitors in cancer therapy
- 8 April 2004
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 206 (2) , 159-167
- https://doi.org/10.1016/j.canlet.2003.08.033
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issuesExpert Opinion on Investigational Drugs, 2000
- RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: Evidenced in vivo by an anti-farnesyl cysteine antibodyProceedings of the National Academy of Sciences, 2000
- Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoBJournal of Biological Chemistry, 1997
- K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase InhibitorsJournal of Biological Chemistry, 1997
- PROTEIN PRENYLATION: Molecular Mechanisms and Functional ConsequencesAnnual Review of Biochemistry, 1996
- Protein PrenyltransferasesJournal of Biological Chemistry, 1996
- Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf ComplexesPublished by Elsevier ,1995
- Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferaseDrug Development Research, 1995
- Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal CellsScience, 1993
- Selective Inhibition of ras -Dependent Transformation by a Farnesyltransferase InhibitorScience, 1993